Searched over 200M research papers
10 papers analyzed
These studies suggest proto-oncogenes require activation through genetic alterations to contribute to cancer development.
20 papers analyzed
Proto-oncogenes are normal genes that play a crucial role in regulating cell growth and proliferation. However, when these genes undergo certain alterations, they can become oncogenes, which have the potential to cause cancer. These alterations can include mutations, chromosomal rearrangements, and gene amplification, leading to the uncontrolled growth of cells and the formation of tumors .
Proto-oncogenes can be activated through various genetic mechanisms. Point mutations in key codons can convert proto-oncogenes into oncogenes, as seen with the ras gene, which is frequently mutated in human tumors. Chromosomal translocations and gene rearrangements can also lead to the activation of proto-oncogenes, as observed in hematopoietic tumors where genes like ret and trk are involved .
Another mechanism of proto-oncogene activation is gene amplification, where the number of copies of a proto-oncogene increases, leading to its overexpression. This has been observed in various human tumors, including early stages of mammary neoplasia with the HER2/neu gene. Amplification is often associated with the later stages of tumor progression but can occur at different stages depending on the type of cancer.
Activated proto-oncogenes contribute to cancer by inhibiting apoptosis, the programmed cell death that normally helps to eliminate damaged cells. This inhibition provides the cancer cells with a form of immortality, allowing them to proliferate uncontrollably .
Proto-oncogenes like MYC play a significant role in altering cell metabolism and growth. MYC activation leads to changes in gene expression that support increased cell growth and proliferation, contributing to tumorigenesis. This includes the activation of genes involved in ribosomal and mitochondrial biogenesis, glucose and glutamine metabolism, and lipid synthesis.
The identification of proto-oncogene proteins as biomarkers is crucial for the early diagnosis of cancer. Advanced computational methods have been developed to predict the presence of proto-oncogenes with high accuracy, aiding in early cancer prognosis and potentially improving patient outcomes.
Understanding the specific mechanisms by which proto-oncogenes are activated provides opportunities for targeted cancer therapies. For instance, targeting the TBK1 gene product has been shown to induce apoptosis in cancer cells with mutant KRAS, highlighting a potential therapeutic strategy.
Proto-oncogenes are essential regulators of normal cell growth and proliferation, but their activation through genetic mutations, chromosomal rearrangements, and gene amplification can lead to cancer. These activated oncogenes contribute to tumorigenesis by inhibiting apoptosis and altering cell metabolism. Advances in the understanding of proto-oncogene activation mechanisms offer promising avenues for early cancer detection and the development of targeted therapies.
Most relevant research papers on this topic